Skip to main content
. Author manuscript; available in PMC: 2026 Aug 18.
Published in final edited form as: Differentiation. 2026 Jun 7;150:100973. doi: 10.1016/j.diff.2026.100973

Fig. 4. Table of all sgRNAs designed and tested in this study.

Fig. 4.

All sgRNA target sequences tested in this study, along with predicted efficacy scores from CRISPOR, namely Doench ’16 and Doench Ruleset 3 (RS3). Norm. ’16 and Norm. RS3 represents normalized Doench ’16 and Doench RS3 scores, in which the represented ranges (not absolute theoretical score ranges) are converted to a scale from 0 to 1. Norm + Ave = normalized Doench ’16 and RS3 scores averaged. Mut. % = mutagenesis efficacy as measured by Amplicon-EZ sequencing. Mut. % scores in blue represent efficacies estimated from size of indel peak, and not the automated efficacies as given by automated Amplicon-EZ analysis (black Mut. % scores).